Orphazyme AS (Orphazyme AS) Current Deferred Revenue : $0.00 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Orphazyme AS Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Orphazyme AS's current deferred revenue for the quarter that ended in Jun. 2022 was $0.00 Mil.

Orphazyme AS Current Deferred Revenue Historical Data

The historical data trend for Orphazyme AS's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Current Deferred Revenue Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Current Deferred Revenue

Get a 7-Day Free Trial

0.08

0.05

0.01

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Current Deferred Revenue	Get a 7-Day Free Trial									-	-	-	-	-

Orphazyme AS Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (Orphazyme AS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (OTCPK:OZYMF) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).